Autoimmune disease Archives

PBC clinical trials: Gannex doses first patient

News and Trends 29 Jun 2022

Deal to advance treatment for autoimmune disease worth $97M

MiroBio, which is developing checkpoint agonists to treat autoimmune disease, has announced the completion of a $97 million deal. The financing is being led by Medicxi with investments from OrbiMed and Monograph Capital and existing investors Oxford Science Enterprises, Samsara Biocapital, SR One and Advent Life Sciences. Funds will primarily be used to advance MiroBio’s […]

June 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 7 Jun 2022

ImmunOs Therapeutics raises $74M

ImmunOs Therapeutics AG, a biopharmaceutical company developing therapeutics for the treatment of cancer and autoimmune diseases, has announced the closing of an oversubscribed Series B financing round totaling $74M. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by other new investors Mission BioCapital, GL Capital, PEAK6 Strategic […]

June 7, 2022 - 3 minutesmins - By Jim Cornall

argenx efgartigimod treatment autoimmune disease myasthenia gravis

News and Trends 21 Dec 2021

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues. Efgartigimod, to be marketed as Vyvgart, is an antibody fragment drug for use in adults with generalized myasthenia gravis. The FDA’s decision represents the first successful drug approval […]

December 21, 2021 - 4 minutesmins - By Anita Chakraverty

Medical anca associated vasculitis avacopan

News and Trends 1 Dec 2021

Targeted Drugs for Rare Autoimmune Disease Hit Regulatory Milestones

New, more targeted treatments are on the horizon for the rare autoimmune disease ANCA-associated vasculitis, with a nod towards European approval for a first-in-class drug and positive phase II results from a rival treatment. In November, the Swiss firm Vifor Fresenius Medical Care Renal Pharma (VFMCRP) received a thumbs-up from the EMA for avacopan, a […]

December 1, 2021 - 4 minutesmins - By Anita Chakraverty

News and Trends 28 Jul 2020

Record Series A for Italian Biotech Funds Autoimmune Therapy

Italian biotech Enthera raised €28M in Series A funding to develop its drug candidate for type 1 diabetes and inflammatory bowel disease and take it to human trials. Enthera was founded in 2016 and is the first company to ‘graduate’ from the BiovelocITA accelerator program in Milan, which is supported by French life science investor […]

July 28, 2020 - 3 minutesmins - By Helen Albert

In Depth 3 Mar 2020

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […]

March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

thyroid eye disease graves disease horizon therapeutics

News and Trends 22 Jan 2020

FDA Greenlights First Treatment for Rare Autoimmune Eye Disease

An antibody drug developed by the Irish biopharma Horizon Therapeutics has been approved by the FDA for the treatment of adults with the rare autoimmune condition thyroid eye disease. The approval of the drug came ahead of schedule, with the decision originally expected in March. The drug, a monoclonal antibody, is branded as Tepezza. Thyroid […]

January 22, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Dec 2019

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […]

December 4, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Nov 2019

Argenx Raises Whopping €502M in Global Offering

The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels. Argenx’s global offering was launched last week. It consists of a private placement in Europe as well as a public offering in the […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2019

European Project Launches to Tailor Autoimmune Disease Treatments

Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […]

October 31, 2019 - 2 minutesmins - By Jonathan Smith

paris ermium therapeutics autoimmune disease

Startup Scout 18 Oct 2019

This Biotech Fights Autoimmune Disease with Rare Immune Cells

We come to the biotech hub of Paris, France, where the biotech Ermium Therapeutics is developing treatments for autoimmune diseases that don’t suppress the whole immune system as current treatments do. Mission: To develop small molecule drugs for autoimmune conditions such as lupus by selectively blocking the activity of a rare type of immune cells […]

October 18, 2019 - 3 minutesmins - By Jonathan Smith

More News! 7 Oct 2019

UK Biotech Launches with €30M Series A to Treat Autoimmune Disease

MiroBio has spun out of the University of Oxford with a Series A round of €30M (£27M) to develop treatments for autoimmune diseases that don’t disrupt the immune system as a whole. The big Series A round accompanying MiroBio’s launch was co-led by the university’s investor partner Oxford Sciences Innovation and the US investor Samsara […]

October 7, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Autoimmune disease

Deal to advance treatment for autoimmune disease worth $97M

ImmunOs Therapeutics raises $74M

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

Targeted Drugs for Rare Autoimmune Disease Hit Regulatory Milestones

Record Series A for Italian Biotech Funds Autoimmune Therapy

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

FDA Greenlights First Treatment for Rare Autoimmune Eye Disease

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

Argenx Raises Whopping €502M in Global Offering

European Project Launches to Tailor Autoimmune Disease Treatments

This Biotech Fights Autoimmune Disease with Rare Immune Cells

UK Biotech Launches with €30M Series A to Treat Autoimmune Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!